Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC
EU grants conditional marketing authorization to the drug Zanidatamab to treat HER2+ BTC.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
Critical update: The FDA puts a hold on the Lorigerlimab trial due to grave safety events, including a deadly incident. Learn more here.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
On the research front, strides are being made in refining management of Immune-checkpoint inhibitors to treat melanoma. Additional information is available here.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
In an important development, the FDA grants Fast Track Designation to SRN-101 for patients with recurring high-grade glioma. Details can be found here.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
In a promising breakthrough, a novel small molecule exhibits early activity in pretreated conditions of multiple myeloma. Further insights here.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
A comparative study evaluates the quality of life outcomes of Protons vs Photons in OPSCC patients. Discover more here.
